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Abstract: The emerging problems posed by antibiotic resistance complicate the treatment regime
required for wound infections and are driving the need to develop more effective methods of wound
management. There is growing interest in the use of alternative, broad spectrum, pre-antibiotic
antimicrobial agents such as essential oils (e.g., tea tree oil, TTO) and metal ions (e.g., silver, Ag+).
Both TTO and Ag+ have broad spectrum antimicrobial activity and act on multiple target sites, hence
reducing the likelihood of developing resistance. Combining such agents with responsive, controlled
release delivery systems such as hydrogels may enhance microbiocidal activity and promote wound
healing. The advantages of using chitosan to formulate the hydrogels include its biocompatible,
mucoadhesive and controlled release properties. In this study, hydrogels loaded with TTO and Ag+
exhibited antimicrobial activity against P. aeruginosa, S. aureus and C. albicans. Combining TTO and
Ag+ into the hydrogel further improved antimicrobial activity by lowering the effective concentrations
required, respectively. This has obvious advantages for reducing the potential toxic effects on the
healthy tissues surrounding the wound. These studies highlight the feasibility of delivering lower
effective concentrations of antimicrobial agents such as TTO and Ag+ in ionically crosslinked chitosan
hydrogels to treat common wound-infecting pathogens.
Keywords: silver; tea tree oil; hydrogels; chitosan; wound management; antimicrobial activity
1. Introduction
The increasing occurrence of antibiotic-resistant strains and reports of hospital cross-infection
further complicate current practices in wound management. Statistics show that acute and chronic
wounds affect approximately 2% of the population, with treatment costs taking up to 4% of the overall
health care budget [1]. In Europe, the cost of managing a patient with chronic wounds can cost up to
€6000–€10,000 per annum [2].
Acute and chronic wounds require relatively lengthy treatment with antibiotics which carry the
attendant risk of developing drug resistance. Additionally, hypersensitivity reactions to antibiotics
and the lack of access to new treatments within the health care industry make the care of such patients
difficult [3]. This severely compromises the patient’s quality of life and also creates a significant
financial burden for the economy. There are, therefore, several forces driving the need to find alternative
approaches to conventional wound management.
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Management of acute and chronic wounds such as varicose insufficiency ulcers, diabetic foot
ulcers and burns aims to minimise infection, speed up wound healing and minimise scarring [4].
Colonisation and subsequent infection of wounds, usually by polymicrobial, opportunistic pathogens,
can delay the healing process, and may lead ultimately to potentially fatal, systemic infection [5].
The diversity and proliferation of the pathogens is influenced by various factors including the type,
depth and location of the trauma, as well as the host immune system response [5]. The presence
of microorganisms at a wound site does not confirm infection [6]. Infection only occurs when the
host immune system can no longer cope with the virulence factors expressed by the colonizing
microorganisms, thus triggering a series of systemic responses which delay the healing process [5,6].
Topical application of antimicrobial agents is a popular approach to wound management since effective
concentrations may be difficult to achieve with systemically delivered drugs [3,7].
The problems posed by increasing antibiotic resistance in Gram-positive (e.g., Methicillin Resistant
Staphylococcus aureus, (MRSA)) and Vancomycin-resistant enterococci) and Gram-negative bacteria
(e.g., New Delhi metallo-β-lactamase-1 and ciprofloxacin-resistant Pseudomonas aeruginosa) [8,9] have
renewed interest in pre-antibiotic antibacterial agents such as essential oils and metal ions [10,11].
The essential oil tea tree oil (TTO) contains >100 different components which contribute to its broad
spectrum antibacterial, antifungal, antiviral, antimycoplasmal, antiprotozoal and anti-inflammatory
activity [12]. Commercially available TTO contains mainly monoterpenes, approximately 50% of which
are oxygenated [13] sesquiterpenes and their associated alcohols [12]. The major component of TTO,
terpinen-4-ol, is primarily responsible for its antimicrobial activity [12]. The hydrophilic hydrocarbon
compounds in TTO have sufficient lipophilicity to allow the oil to partition preferentially into biological
membranes resulting in bilayer expansion [12]. TTO components can easily diffuse through the
hydrophobic lipid bilayer of the microbial cell membrane, causing disruption to integrity and function,
increased fluidity, loss of permeability and inhibition of embedded membrane enzymes. Consequently,
the cell loses essential metabolites and repair enzymes, ultimately resulting in cell death [12,13].
The microbiocidal properties of active monoterpenes are mainly attributed to disruption of the cell
membrane’s barrier function; cells are thus unable to establish control over membrane-coupled
energy-transducing processes, solute transport, regulation of metabolism and maintenance of turgor
pressure [13]. Preparations containing TTO are commonly used for their antiseptic, antimicrobial,
cleansing, healing and itch-relieving properties [14]. In addition, TTO is widely used in wound
management for its antimicrobial and therapeutic properties: e.g., Burnaid® (Rye Pharmaceuticals,
Roseville, NSW, Australia) is a commercial hydrogel dressing impregnated with TTO for the treatment
of burns [15]. The topical application of TTO is not without its problems, however; there are reports
of dermal toxicity of TTO resulting in irritation and allergic reactions [12]. The use of TTO-based
dressings on large areas of the skin whilst providing a desirable localized cooling effect on burns may
trigger an unwanted hypothermic response [15].
Silver ions (Ag+) have regained popularity as an antimicrobial agent due to their broad spectrum
antibacterial, antiviral, antiprotozoal and antifungal activity [16]. Ag+ are classified as highly reactive
moieties, which readily bind anions formed by electron donor groups containing sulphur (thiols),
oxygen and nitrogen [16]. The mode of action involves the inactivation of membrane-bound proteins,
resulting in morphological cellular changes, inhibition of cell replication [17,18] and impairment of
solute and electron transport systems. This interferes with the activity of essential intracellular enzymes
and DNA, leading to reduced production of vital cell components, such as adenosine triphosphate
(ATP) [16,18–20]. The ability of Ag+ to affect multi-target sites is beneficial to reduce the potential
development of resistant strains [21]. In addition, Ag+ has been reported to enhance wound healing
directly by modulating the inflammatory response [22]. The antimicrobial activity and inflammatory
regulation activities of Ag+ are of interest in the development of improved wound management
products. Formulations containing silver are commonly used to treat a variety of Gram-positive
and Gram-negative bacteria, as well as common highly-antibiotic-resistant microorganisms such as
P. aeruginosa [18]. Silver-based pharmaceutical preparations, e.g., silver sulfadiazine (Flamazine®,
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Smith and Nephew Healthcare Limited, Hull, UK), have been successfully used for the treatment of
burn wound infections. In addition, controlled release delivery systems have also incorporated Ag+ to
reduce infection and improve the wound healing process. Some current examples of silver-containing
wound dressings include DuoDERM® (hydrocolloids, ConvaTec, Skillman, NJ, USA), Aquacel® Ag
(hydrofibre dressings containing antimicrobial Ag+, ConvaTec, Skillman, NJ, USA), TegadermTM
(films, 3M United Kingdom PLC, Bracknell, UK), VaselineTM (gauze, Unilever, London, UK), Sorbsan®
(alginates, Bertel Pharmacceuticals, Research Triangle Park, NC, USA), Lyofoam® C (foam dressing,
ConvaTec, Skillman, NJ, USA) and Nu-GelTM (hydrogels, Johnson and Johnson Wound Management,
Somerville, NJ, USA) [23,24]. As is common with many drug treatments, over-exposure to Ag+ can
trigger unwelcome side effects. Long-term topical exposure to high concentrations of Ag+ leads to
a build-up of metallic silver (Ag0) in the dermis, causing an irreversible blue-grey discolouration of
the skin (argyria). This is particularly pronounced in areas exposed to sunlight which accelerates
the photo-reduction and deposition of Ag0 [25–27]. Some patients treated with silver-containing
dressings reported the occurrence of skin rashes, stinging and burning sensations [28]. Other more
serious problems associated with the topical application of silver include disturbances in electrolyte
concentration resulting in hyponatremia or hypochloremia [20].
Hydrogels are three-dimensional crosslinked polymer networks which can imbibe large
amounts of water or biological fluids [4,29]. These biodegradable gels maintain their structure
during the exchange of fluids and provide controlled release of drugs via pores in the polymer
network [29,30]. When applied to wounds, hydrogels can absorb exudate while maintaining a
well-oxygenated and moist environment [31,32]. The parameter that dictates hydrogel formation
is the constituent polymer’s aqueous solubility, whether it is from natural or synthetic sources.
Chitosan, a natural polymer amenable to hydrogel formation, is a linear copolymer of β(1-4)-linked
2-acetamido-2-deoxy-D-glucopyranose and 2-amino-2-deoxy-D-glyco-pyranose monomers [32].
Chitosan has good biocompatibility, biodegradability, mucoadhesive and low toxicity properties.
It forms a barrier to gases and aromas in dry conditions, and is used to prepare membranes, films,
microparticles, nanofibrils, scaffolds and gels [33–35]. Chitosan’s properties can be adapted to
suit a wide variety of antimicrobial delivery systems for medical, food, coating and packaging
applications. In addition, chitosan has bacteriostatic properties against fungi and Gram-negative
bacteria. The advantages of using chitosan for wound management applications are its biocompatible,
mucoadhesive and controlled release properties. This allows cell adhesion and interactions
which promote the growth of dermal and epidermal layers by inducing cell migration as well as
proliferation [35,36].
The useful properties of alternative antimicrobial agents, together with advances in drug delivery
technologies, may be able to enhance and expand the medical applications of these agents. Combining
these alternative antimicrobial agents with advanced drug delivery systems aims to: (1) promote
bioavailability of the agent at microbiocidal concentrations; (2) reduce drug concentration to enhance
safety and practicality of application; (3) minimise scarring and promote wound healing processes;
(4) reduce discomfort and pain in consideration of the patients’ psychological needs; and (5) decrease
the frequency of dressing changes [37]. These aims would increase convenience, provide less
opportunity for infection and/or reinfection of the wound and ultimately reduce treatment costs.
Therefore, the aims of this investigation were to examine the in vitro antimicrobial efficacy of
hydrogels incorporating TTO alone and in combination with Ag+ (as silver nitrate, AgNO3) against
representative wound-infecting organisms, namely P. aeruginosa, S. aureus and C. albicans. We report
here on the characterisation and optimisation of both preparation and formulation techniques of a
hydrogel-based delivery system for controlled release of antimicrobially active Ag+ and TTO.
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2. Materials and Methods
2.1. Preparation of Microbial Cultures
Sterile tryptone soy broth (TSB), tryptone soy agar (TSA), malt extract broth (MEB) and malt extract
agar (MEA) were obtained from Lab M, Lancashire, UK, and prepared according to manufacturer’s
recommendations. Overnight culture of P. aeruginosa (NCIB 8295) was prepared by aseptically
inoculating 50 mL of sterile TSB and incubating overnight in an orbital shaker at 37 ˝C. Similarly,
overnight cultures of S. aureus (NCIB 6571) in TSB and C. albicans (NCYC 854) in MEB were also
similarly prepared.
2.2. Hydrogel Formulation and Characterisation
Sodium phosphate (monobasic monohydrate, Sigma Aldrich, Darmstadt, Germany), Na-P
solutions (25% and 50% w/v) were prepared in sterile distilled water. Medium- or low-viscosity
chitosan (Sigma Aldrich, Darmstadt, Germany) solutions (1.25% and 2.5% w/v) were prepared in
1.0% v/v glacial acetic acid (BDH, Poole, UK). Phosphate buffer saline (PBS) (Invitrogen Corporation,
Camarillo, CA, USA) was prepared according to manufacturer’s recommendation and autoclaved
prior to use.
Ionically crosslinked chitosan hydrogels were prepared by vigorous magnetic stirring of various
ratios of chitosan (medium or low viscosity, 1.25% or 2.5% w/v), Na-P (25% or 50% w/v) and 10% w/v
poly(vinyl alcohol) (PVA) 13–23 kDa, PVA13´23, or 31-50kDa, PVA31´50, (Sigma Aldrich, Darmstadt,
Germany) solutions. After mixing for 2 min the gelling mixtures were passed through 0.45 µm sterile
syringes, transferred into sterile Petri dishes, covered and allowed to set for a minimum of 2 h.
The physical stability of each formulation was assessed firstly by confirming the formation of a
uniform hydrogel. Following that, discs of hydrogel (diameter 8 mm) were cut and placed in a clean
Petri dish with 20 mL of distilled water. Hydrogel formulation discs that maintained their shape, could
easily be cut out and handled, as well as remaining stable after incubation in water were chosen for
further study.
TTO:PVA (poly[vinyl alcohol]) emulsions were prepared by probe sonicating (Bandelin Sonopuls
HD2200, Bandelin Electronic, Berlin, Germany) TTO and 10% w/v PVA (35:65 v/v ratio) for 1 min.
TTO:PVA-loaded hydrogels were prepared by substituting or adding sufficient emulsified TTO as part
of the PVA component in the formulations to produce hydrogels with final TTO concentration of 5% or
7% v/v.
TTO-encapsulated hydrogel discs (8 mm diameter) were incubated in 20 mL PBS at room
temperature. At time zero and at every hour up to 6 h, 6 mL of PBS was sampled, and replaced
by 6 mL of fresh PBS. Further samples were taken after 7.5 and 24 h. Subsequently the amount of
TTO and chitosan released from the hydrogels was quantified using the monoterpene and ninhydrin
quantification assays, respectively.
2.3. Vanillin Assay for the Determination of Monoterpene Release from TTO
A colorimetric method for determining the total monoterpene content using 2.5% w/v vanillin
(ReagentPlus® grade, Acros Organics, Geel, Belgium) in concentrated sulphuric acid (Philip Harris
Scientific, Lichfield, UK) was adapted from Doneva-Šapceska et al., 2006 [38]. Vanillin reagent (2.5 mL)
was added to test tubes containing 5 mL of sample, mixed and heated in a 60 ˝C water bath for 20 min.
The samples were then cooled in an ice-water bath to 25 ˝C. A blank sample was also prepared using
5 mL distilled water. Absorbance of the samples was measured spectrophotometrically at 608 nm
(Cecil 1000 Series, Cecil Instruments, Cambridge, UK).
2.4. Chitosan Assay (Ninhydrin Assay)
Quantification of chitosan was performed using a colorimetric ninhydrin assay adapted from
Leane et al., 2004 [39]. Lithium acetate buffer (4 M) was prepared by dissolving 4.08 g of lithium
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acetate dihydrate (Aldrich grade 98%, Sigma Aldrich, Milwaukee, WI, USA) in 10 mL distilled water
and adjusted to pH 5.2 using glacial acetic acid. Ninhydrin reagent was prepared by adding 0.8 g
ninhydrin (ACS reagent, Sigma Aldrich, Bangalore, India) and 0.12 g hydrindantin (Sigma Aldrich,
Vienna, Austria) in 30 mL dimethylsulphoxide (DMSO) (Calbiochem, EMD Chemicals, San Diego, CA,
USA) into 10 mL of 4 M lithium acetate buffer. Ninhydrin reagent (0.5 mL) was added to 0.5 mL of
sample in a capped test tube. Blanks sample were prepared by substituting the sample with distilled
water. The contents were mixed and heated in boiling water for 30 min, cooled and 15 mL of 50:50
ethanol:water cosolvent mixture added. The contents of each tube were vortexed for 15 s to ensure
complete oxidization of the excess hydrindantin, prior to measuring absorbance spectrophotometrically
at 570 nm (Cecil 1000 Series). The results were analysed by fitting the data to zero order, first order,
Higuichi and Korsmeyers-Peppas equations [40] to deduce the monoterpene release profile from
the hydrogels.
2.5. Formulation of Ag+ and TTO:Ag+:PVA for Antimicrobial Studies
Following the initial trial formulations confirming the feasibility of hydrogels to deliver TTO,
another batch of hydrogels containing 35% TTO: 65% PVA30´70 v/v, Ag+ and TTO:Ag+:PVA30´70 were
produced. It was found that the Ag+ solutions used in the formulations also acted as the crosslinker
for the hydrogels; hence, in the formulations containing Ag+, Na-P was substituted with 1% or 2%
w/v AgNO3. The emulsion of TTO:Ag+:PVA30´70 was prepared by dissolving sufficient AgNO3 in
10% w/v PVA30´70, adding sufficient TTO and sonicating the mixture for 3 min. The concentration of
TTO:Ag+:PVA30´70 used were as follows:
I 40% TTO: 0.5% AgNO3
II 20% TTO: 1.0% AgNO3
Table 1 shows the detailed composition of stable hydrogels containing TTO and/or Ag+, which
were used for antimicrobial studies.
2.6. Well Diffusion Assay to Determine the Antimicrobial Activity of Hydrogels
The antimicrobial effect of the agents encapsulated into hydrogels was tested using a standard well
diffusion method. Overnight cultures of P. aeruginosa and S. aureus were adjusted accordingly to the
following absorbance reading at 500 nm based on the British Society for Antimicrobial Chemotherapy
(BSAC) disc diffusion method guidelines [41]:
‚ P. aeruginosa ´> 0.1´0.3
‚ S. aureus ´> 0.3´0.6
Overnight cultures of C. albicans were used without dilution in the disc diffusion experiments,
as they contained sufficient number of cells for the experiments. The adjusted cultures were
swabbed on the surface of the agar plates in triplicate according to the BSAC disc diffusion method
recommendations. A well (12 mm diameter) was aseptically bored in the middle of the agar plate
using a sterile metal borer. The hydrogel was aseptically placed in the well and incubated overnight at
37 ˝C, prior to measuring the diameter of the zone of inhibition. Control experiments were prepared
by substituting the hydrogels with those formulated without TTO:PVA and AgNO3.
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Table 1. Formulation details of hydrogels containing Tea tree oil (TTO) and/or silver ions (Ag+).
I. TTO Hydrogels.
Effective Amount
of TTO (% v/v)







PVA30´70 (mL)1.25% w/v 2.50% w/v
6.667 CL2.5(10)Na-P50(7)TTO35(4) - 10.00 - 7.00 4.00 -
6.667 CL1.25(17)Na-P25(17)TTO35(8) 17.00 - 17.00 - 8.00 -
6.667 CL1.25(8)Na-P25(9)TTO35(4) 8.00 - 9.00 - 4.00 -
8.333 CL2.5(7)Na-P25(9)TTO35(5) - 7.00 9.00 - 5.00 -
6.667 CM2.5(12.5)Na-P50(2.5)TTO35(4) - 12.50 - 2.50 4.00 -
8.333 CM2.5(11.75)Na-P25(4.25)TTO35(5) - 11.75 4.25 - 5.00 -
6.667 CM2.5(12)Na-P25(5)TTO35(4) - 12.00 5.00 - 4.00 -
6.667 CM1.25(12)Na-P50(5)TTO35(4) 12.00 - - 5.00 4.00 -
6.667 CH2.5(10)Na-P50(1)TTO35(4)PVA10(6) - 10.00 - 1.00 4.00 6.00
6.667 CH1.25(13)Na-P50(4)TTO35(4) 13.00 - - 4.00 4.00 -
6.667 CH2.5(22)Na-P50(7)TTO35(8)PVA10(5) - 22.00 - 7.00 8.00 5.00
6.667 CH1.25(10)Na-P25(7)TTO35(4) 10.00 - 7.00 - 4.00 -




of Ag+ (% w/v) Hydrogel Formulation






Vol. of 2% w/v
AgNO3 (mL)
Vol. of 10%
PVA30´70 (mL)1.25% w/v 2.50% w/v
0.212 CL2.5(28)Ag2(7)PVA10(7) - 28.0 - - 7.0 7.0
0.159 CL2.5(10.5)Ag0.75(7)PVA10(3.5) - 10.5 7.0 - - 3.5
0.726 CL1.25(9)Ag2(12) 9.0 - - - 12.0 -
0.635 CL1.25(10.5)Ag2(10.5) 10.5 - - - 10.5 -
0.786 CL1.25(8)Ag2(13) 8.0 - - - 13.0 -
0.151 CM2.5(10)Ag1(5)PVA10(6) - 10.0 - 5.0 - 6.0
0.212 CM2.5(7)Ag1(7)PVA10(7) - 7.0 - 7.0 - 7.0
0.605 CM1.25(22)Ag2(20) 22.0 - - - 20.0 -
0.635 CM1.25(10.5)Ag2(10.5) 10.5 - - - 10.5 -
0.061 CH2.5(14)Ag2(2)PVA10(5) - 14.0 - - 2.0 5.0
0.423 CH1.25(14)Ag2(7) 14.0 - - - 7.0 -
0.635 CH1.25(14)Ag2(10.5) 14.0 - - - 10.5 -
III. Ag+ + TTO: PVA Hydrogels.
Effective Amount
of TTO (% v/v)
Effective Amount
of Ag+ (% w/v) Hydrogel Formulation
Vol. of Chitosan (mL) Vol. of 20% TTO:
0.5% AgNO3 (mL)
Vol. of 20% TTO: 1%
AgNO3 (mL)
Vol. of 25% Na-P (mL)
Volume of 10%
PVAp30´70q (mL)1.25% w/v 2.50% w/v
5.714 0.045 CL1.25(12)TTO-Ag20´0.5p3qNa-P25(1)PVA10(5) 12.00 - 3.00 - 1.00 5.00
6.667 0.212 CL2.5(14)TTO-Ag20´1p7q - 14.00 - 7.00 - -
10.950 0.348 CL1.25(9.5)TTO-Ag20´1p11.5q 9.50 - - 11.50 - -
5.714 0.045 CM1.25(12)TTO-Ag20´0.5p3qNa-P25(0.75)PVA10(5.25) 12.00 - 3.00 - 0.75 5.25
5.714 0.181 CM2.5(11)TTO-Ag20´1p6qPVA10(4) - 11.00 - 6.00 - 4.00
13.333 0.106 CM2.5(7)TTO-Ag20´1p7qPVA10(7) - 7.00 - 7.00 - 7.00
10.480 0.333 CM1.25(10)TTO-Ag20´1p11q 10.00 - - 11.00 - -
1.795 0.057 CH2.5(21.5)TTO-Ag20´1p3.5qPVA10(14) - 21.50 - 3.50 - 14.00
6.667 0.053 CH2.5(10.5)TTO-Ag20´0.5p3.5qPVA10(7) - 10.50 3.50 - - 7.00
8.571 0.272 CH1.25(12)TTO-Ag20´1p9q 12.00 - - 9.00 - -
9.524 0.302 CH1.25(11)TTO-Ag20´1p10q 11.00 - - 10.00 - -
10.000 0.318 CH1.25(10.5)TTO-Ag20´1p10.5q 10.50 - - 10.50 - -
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3. Results and Discussion
3.1. Appearance of Ionically Crosslinked Chitosan Hydrogels
Data from the preliminary studies showed that stable, uniform hydrogels were formed using
the composition ratios as detailed in Table 2. All the hydrogel formulations reported in Table 2 could
easily be cut out as 8 mm or 12 mm diameter discs, remained stable when incubated in PBS and did
not break up extensively over the incubation period. Examples of the appearance of the formulated
hydrogels are shown in Figure 1.
Table 2. Composition of stable hydrogel formulations grouped according to chitosan concentration
and viscosity.
I. 1.25% w/v chitosan low viscosity (ChitosanL1.25).
ChitosanL1.25
10% PVA (% w/v) 25% Na-P
(% w/v)
Formulation Code
on Graph Hydrogel Appearance13–23 kDa 31–50 kDa
4 2 - 1 CL1.25PVA13´23 Overall smooth + soft gel
4 - 2 1 CL1.25PVA31´50 Overall smooth + soft gel
II. 2.5% w/v chitosan low viscosity (ChitosanL2.5).
ChitosanL2.5
10% PVA (% w/v) 25% Na-P
(% w/v)
Formulation Code
on Graph Hydrogel Appearance13–23 kDa 31–50 kDa
4 1 - 1 CL2.5PVA13´23 Overall smooth + soft gel
4 - 2 1 CL2.5PVA31´50 Overall smooth + soft gel
III. 1.25% w/v chitosan medium viscosity (ChitosanM1.25).
ChitosanM1.25
10% PVA (% w/v) 25% Na-P
(% w/v)
Formulation Code
on Graph Hydrogel Appearance13–23 kDa 31–50 kDa
3 1 - 2 CM1.25PVA13´23 Rough surface + soft gel
4 - 2 1 CM1.25PVA31´50 Overall smooth + soft gel
IV. 2.5% w/v chitosan medium viscosity (ChitosanM2.5).
ChitosanM2.5
10% PVA (% w/v) 25% Na-P
(% w/v)
Formulation Code
on Graph Hydrogel Appearance13–23 kDa 31–50 kDa
4 2 - 1 CM2.5PVA13´23 Slightly flakey + soft gel
4 - 1 3 CM2.5PVA31´50 Rough surface + flakey + dry gel
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Figure 1. Appearance of ionically crosslinked hydrogels. (a): Hydrogels with a slightly flakey but
overall smooth surface; (b) Hydrogels with soft texture and r ugh surface; (c) Semi-gel, soft hydrogels
with flakey and dry surface ; (d) Hydrogels with dry, flakey, rough surface.
3.2. Cumulative Chitosan and Monoterpene Release after 24 h Incubation
The releas mechanism of chitosan and monoterpene (TTO) ro hydrogels was investigated
as a function of hydrogel degradation. Figure 2 shows the release profiles of low-viscosity chitosan
(Figure 2A) and medium-viscosity chitosan (Figure 2B) of hydrogel formulations containing 35% TTO:
65% PVA (10% w/v) emulsion. The release profiles of chitosan from formulations containing 50% TTO:
50% PVA (10% w/v) are shown in Figure 2C. Similarly, the monoterpene release profiles from the
respective hydrogel formulations are shown in Figure 3.
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Figure 2. Cumulative release of (A) low-viscosi chitosan; and (B) medium-viscosity hitosan from
hydrogel formulations containing TTO: 10 w/v PVA (35:65 v/v ratio); and (C) mediu -viscosity
chitosan from hydrogel formulations containing TTO: 10 w/v PVA (50:50 v/v ratio). A sub-graph has
been provided in both (B, C) to provide an overview of the amount of released chitosan in comparison
to (2A). The codes shown in the figure key describe the following: CL1.25 = 1.25% w/v low-viscosity
chitosan, CL2.5 = 2.5% w/v low-viscosity chitosan, CM1.25 = 1.25% w/v medium-viscosity chitosan,
CM2.5 = 2.5% w/v medium-visco ity chitosan, PVA13´23 = PVA 13– 3 kDa, PVA31´50 = PVA 31–50 kDa.
The error bars represents the standard deviation and n = 3.
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Low‐viscosity  chitosan  formulations  showed  chitosan  release  was  between  9.72  ×  10−2  to   
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Figure 3. Cumulative release of monoterpene from (A) low-viscosity chitosan; and (B)
medium-viscosity chitosan hydrogel formulations containing TTO: 10% w/v PVA (35:65 v/v ratio); and
(C) medium-viscosity chitosan hydrogel formulations containing TTO: 10% w/v PVA (50:50 v/v ratio).
The codes shown in the figure key describes the following: CL1.25 = 1.25% w/v low-viscosity chitosan,
CL2.5 = 2.5% w/v low-viscosity chitosan, CM1.25 = 1.25% w/v medium-viscosity chitosan, CM2.5 = 2.5%
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Low-viscosity chitosan formulations showed chitosan release was between 9.72 ˆ 10´2 to
3.99 ˆ 10´1 %/mL at 24 h post-incubation (Figure 2A). Comparatively, the amount of monoterpene
release was fairly similar, i.e., 2.53 ˆ 10´1 to 3.52 ˆ 10´1 %/mL (Figure 3A). Results showed that
lower-viscosity hydrogels and those formulated using PVA13´23 (to emulsify the TTO prior to
encapsulation) eroded at a higher rate (more chitosan released). The hydrogels formulated with
PVA13´23 and chitosanL1.25 released 3.99 ˆ 10´1 %/mL compared to 2.07 ˆ 10´1 %/mL in gel
formulated using chitosanL2.5. Similarly, in hydrogels formulated with PVA31´50, stability was also
improved in gels formulated with chitosanL2.5, resulting in 9.72 ˆ 10´2 %/mL chitosan release
compared to 2.99 ˆ 10´1 %/mL in the gel formulated using chitosanL1.25.
The trend of chitosan and monoterpene release from hydrogels formulated with medium-viscosity
chitosan differs from the low-viscosity hydrogels. Results in Figures 2B and 3B showed
that chitosanM1.25 formulations gradually released both chitosan and monoterpene over time.
The formulation having a higher volume of 25% w/v Na-P (formulation CM1.25PVA13´23) displayed
better stability properties, i.e., low chitosan release (low erosion) with slow release of monoterpene.
In contrast, formulations with chitosanM2.5 showed a steep increase in chitosan release between 5 and
7.5 h post-incubation, resulting in the higher final amount released. Although the gels formulated
with chitosanM2.5 are considered to be more stable, those formulated with PVA13´23 (formulation
CM2.5PVA13´23) may be more prone to erosion due to the lower chitosan:Na-P ratio, resulting in weaker
crosslinking. Similarly, the stability of the gels may also be compromised by the chitosan-PVA chain
entanglement interaction. Hence, despite the higher chitosan:Na-P ratio, the gels formulated with
PVA31´50 (formulation CM2.5PVA31´50) appear to be less stable (greater chitosan erosion) due to the
dissociation of the chitosan-PVA interaction. Consequently, this also resulted in higher monoterpene
release, despite the more viscous properties of these formulations within the group.
When formulating medium-viscosity hydrogels with 50% TTO:50% PVA v/v, there were
observable changes in the chitosan and monoterpene release profiles (Figures 2C and 3C). The overall
chitosan release from the formulations was lower when compared to the formulations in Figure 2B.
All formulations showed gradual increase of chitosan release over time, except formulation
CM1.25PVA31´50 in Figure 2C, which showed a steep increase between 4 and 6 h post-incubation.
Similar to the other formulations, increasing crosslinking along with increased viscosity improves
hydrogel stability. These gels (CM1.25PVA13´23 and CM2.5PVA31´50 in Figure 3C) showed a gradual
increase in monoterpene release up to 5.65 ˆ 10´1 %/mL and 4.95 ˆ 10´1 %/mL, respectively.
On the other hand, monoterpene release in the formulations having a lower ratio of chitosan:Na-P
(less viscous) was between 7.65 ˆ 10´2 and 1.19 ˆ 10´1 %/mL. When monoterpene release for
hydrogel formulations was analysed with zero order, first order, Higuchi and Korsmeyer-Peppas
equations [40], the results indicated that monoterpene release from the all the hydrogel formulations,
except formulation CM1.25PVA13´23, follows the zero order release with a correlation coefficient of
R > 0.97, i.e., release of monoterpene was constant over time [40]. The correlation coefficients for the
other models (first order release, Korsmeyers-Peppas and Higuchi models) were all <0.97 (Table 3).
Based on the mathematical modelling, the release profile of formulation CM1.25PVA13´23 fits the
Higuichi equation (R2 > 0.97); hence, the monoterpene was released via a diffusional process according
to Fick’s law [40].
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Table 3. Mathematical modelling of monoterpene release from the hydrogel formulations.
Formulation
Correlation Co-Efficient (R2)
Zero Order First order Higuichi Korsmeyers-Peppas
CL1.25PVA13´23 0.98 0.72 0.95 0.75
CL1.25PVA31´50 0.99 0.77 0.94 0.80
CL2.5PVA13´23 0.98 0.86 0.86 0.90
CL2.5PVA31´50 0.99 0.76 0.96 0.77
CM1.25PVA13´23 0.93 0.79 0.98 0.85
CM1.25PVA31´50 0.98 0.83 0.89 0.91
CM2.5PVA13´23 >0.99 0.88 0.90 0.92
CM2.5PVA31´50 0.99 0.83 0.94 0.85
Preferably, TTO-hydrogel formulations should be tailored to have lower chitosan release along
with more controlled monoterpene release, thus indicating increased formulation stability with
sustained delivery of TTO to maintain antimicrobial efficacy. It is evident that there are many factors
which may influence the viscosity and properties of each formulation.
3.3. Well Diffusion Assay of Hydrogels Containing TTO and/or Ag+
The results from the well diffusion assay showed antimicrobial activity in the presence of the
agents both singly and in combination. Increasing the viscosity of chitosan from low to high effectively
increases the respective molecular weight and polymeric chain length [42], which results in potentially
greater inter-chain entanglement, hence affecting its viscosity and ability to release the antimicrobial
agents. The antimicrobial activity of the formulations will be discussed separately based on the type of
agent and chitosan viscosity.
The effect of TTO-hydrogel (low viscosity) formulations follows an order of sensitivity similar
to that of the minimum lethal concentration (MLC) reported in Low et al. (2011) [43] for free TTO,
i.e., C. albicans > S. aureus ě P. aeruginosa (Figure 4A). Results showed little changes in the zones of
inhibition (ZOI) against P. aeruginosa, possibly due to the higher tolerance of P. aeruginosa to TTO. In
Figure 4A, the formulations CL1.25(17)Na-P25(17)TTO35(8)-CL2.5(7)Na-P25(9)TTO35(5) vary with increasing
viscosity and amount of crosslinker which can improve gel stability. This resulted in more stable TTO
hydrogels which can entrap more of the essential oil; the improved antimicrobial activity is observed
by an increased ZOI for microorganisms with higher TTO sensitivity, e.g., C. albicans. Despite increased
formulation stability (CL1.25(17)Na-P25(17)TTO35(8)-CL2.5(7)Na-P25(9)TTO35(5)), the ZOI for less sensitive
microorganisms, e.g., P. aeruginosa and S. aureus, has not been significantly affected (p > 0.05). This may
be due to the slower rate of TTO release (from more stable hydrogels) which limits the availability of
the agent at microbiocidal concentrations, and thus the ZOI for less sensitive microorganisms are not
affected. Conversely, formulation CL2.5(10)Na-P50(7)TTO35(4) had the lowest chitosan: Na-P ratio which
makes it less stable and more prone to faster erosion and drug release, resulting in a burst release of
TTO which leads to a higher ZOI after 24 h incubation. Such immediate burst release with concomitant
rapid hydrogel erosion is not particularly useful when treating wounds with heavy microbial loads.
Formulations therefore need to be optimised to reduce the rate of erosion and degradation of the
hydrogel whilst maintaining prolonged delivery of agents at microbiocidal concentrations.
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deviation and n = 3. In all control experiments (using hydrogels without TTO), there was no observed 
zone of inhibition (ZOI) (data not shown). Statistical analysis using ANOVA indicated a significant 
difference  in  the  antimicrobial  activity  of  the  formulations  against  the  selected microorganisms   
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high viscosity chitosan, Na‐P25 = 25% w/v sodium phosphate, Na‐P50 = 50% w/v sodium phosphate, 
TTO35  =  emulsion of TTO:PVA30‐70  (35:65  v/v  ratio), PVA = PVA  30‐70kDa  and  the volume of  the 
components used in each formulation are shown in the brackets. 
Figure 4. Antimicrobial activity of TTO-hydrogels formulated with (A) low viscosity chitosan,
(B) medium viscosity chitosan and (C) high viscosity chitosan. Error bars represent the standard
deviation and n = 3. In all control experiments (using hydrogels without TTO), there was no observed
zone of inhibition (ZOI) (data not shown). Statistical analysis using ANOVA indicated a significant
difference in the antimicrobial activity of the formulations against the selected microorganisms
(p < 0.05). The codes shown in the figure key describes the following: CL1.25 = 1.25% w/v low viscosity
chitosan, CL2.5 = 2.5% w/v low viscosity chitosan, CM1.25 = 1.25% w/v medium viscosity chitosan,
CM2.5 = 2.5% w/v medium viscosity chitosan, CH1.25 = 1.25% w/v high viscosity chitosan, CH2.5 =
2.5% w/v high viscosity chitosan, Na-P25 = 25% w/v sodium phosphate, Na-P50 = 50% w/v sodium
phosphate, TTO35 = emulsion of TTO:PVA30´70 (35:65 v/v ratio), PVA = PVA 30-70kDa and the volume
of the components used in each formulation are shown in the brackets.
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Results from Figure 4B did not show significant ZOI changes with increasing stability
(CM2.5(11.75)Na-P25(4.25)TTO35(5)-CM1.25(12)Na-P50(5)TTO35(4)) against P. aeruginosa. The ZOI in hydrogels
CM2.5(12.5)Na-P50(2.5)TTO35(4) and CM1.25(12)Na-P50(5)TTO35(4) follows the MLC sensitivity trend of
C. albicans > S. aureus > P. aeruginosa. However, the extent of antimicrobial activity, especially
against the more sensitive C. albicans, is lower than those formulated with low-viscosity chitosan
(CL2.5(10)Na-P50(7)TTO35(4)-CL2.5(7)Na-P25(9)TTO35(5)). This reduce in antimicrobial activity is probably
due to the overall increase in chitosan chain length (moving from low to medium viscosity), which
potentially increases inter-chain entanglement, hence retarding the ability of TTO diffusion and
thereby reducing the amount released from the hydrogel structure. Within this group, formulation
CM2.5(12.5)Na-P50(2.5)TTO35(4) (lowest chitosan:Na-P ratio) forms a less stable hydrogel with a higher
rate of erosion; the reduced crosslinking also contributes to a less stable gel network to maximise
TTO:PVA encapsulation by allowing chain entanglement interactions between PVA and chitosan.
As a result, TTO escape from the hydrogel may again follow a burst release profile and increase
the ZOI for C. albicans and S. aureus. However, the concentration was insufficient to show a clear
ZOI for P. aeruginosa, although there was an observed zone of restricted growth with an average
diameter of 30.33 mm. Formulations CM2.5(12)Na-P25(5)TTO35(4) and CM1.25(12)Na-P50(5)TTO35(4) are
more stable due to their increased viscosity (there is more chitosan in the formulation which is
not diluted by the addition of aqueous Na-P). Despite having the same chitosan:Na-P ratio, the
antimicrobial performance of CM2.5(12)Na-P25(5)TTO35(4) and CM1.25(12)Na-P50(5)TTO35(4) was different.
This may be due to the variations in Na-P concentration, which can alter crosslinking and viscosity
of hydrogels (CM2.5(12)Na-P25(5)TTO35(4) formulated using 25% w/v Na-P, CM1.25(12)Na-P50(5)TTO35(4)
formulated using 50% Na-P). Such properties include both the viscosity of the various chitosan
solutions and the ability of oppositely charged crosslinking phosphate anions to diffuse into the
solution and form an electrostatically crosslinked semi-solid structure. The order of sensitivity in
formulation CM2.5(11.75)Na-P25(4.25)TTO35(5) was altered to S. aureus > C. albicans > P. aeruginosa, which
could have resulted from the higher concentration of TTO present in the hydrogels.
Figure 4C showed that antimicrobial activity of hydrogels formulated with high-viscosity
chitosan against C. albicans increased with increasing viscosity. The ZOI against S. aureus
remained fairly consistent, possibly due to the increased gel stability and higher encapsulation
of TTO and its components, which are subsequently available for release. Formulation
CH2.5(10)Na-P50(1)TTO35(4)PVA10(6)-CH2.5(22)Na-P50(7)TTO35(8)PVA10(5) showed no clear ZOI against
P. aeruginosa; however, similar to formulation CM1.25(12)Na-P50(5)TTO35(4), there was an insufficient
concentration of TTO to result in a clear ZOI and zones of restricted growth with average diameters
of 13.5 mm (CH2.5(10)Na-P50(1)TTO35(4)PVA10(6)), 33.0 mm (CH1.25(13)Na-P50(4)TTO35(4)) and 30.667
mm (CH2.5(22)Na-P50(7)TTO35(8)PVA10(5)) were observed. Formulation CH1.25(10)Na-P25(7)TTO35(4) was
shown to have a ZOI against P. aeruginosa. The results in Figure 4 indicated that changes in
hydrogel composition can affect their respective antimicrobial activities, possibly due to alterations in
physicochemical properties of the gels.
The activity of Ag+ hydrogels will be discussed based on the viscosity of chitosan and
concentration of AgNO3 because it has electrostatic crosslinking properties that affect the stability
of the resultant hydrogels as well as their antimicrobial activity. In Ag+ hydrogels, the order of
sensitivity also follows the MLC order of Ag+ reported in Low et al., 2011 [43], i.e., C. albicans >
P. aeruginosaě S. aureus (Figure 5), when the concentration of Ag+ is >0.2117% w/v. However, when the
concentration is ď0.2117% w/v Ag+ (formulation CL2.5(28)Ag2(7)PVA10(7), CL2.5(10.5)Ag0.75(7)PVA10(3.5),
CM2.5(10)Ag1(5)PVA10(6), CM2.5(7)Ag1(7)PVA10(7) and CH2.5(14)Ag2(2)PVA10(5)), the order changes to
P. aeruginosa > S. aureus ě C. albicans. Experimental results also showed that as Ag+ diffuses into the
MEA, a precipitate is formed in the agar. This can reduce the bioavailability of Ag+ against C. albicans,
resulting in a shift in the order of sensitivity. Despite its role as a crosslinker, the antimicrobial activity
of Ag+ is not affected if there are sufficient metal ions available for release from the hydrogel matrix
(refer to Figure 5).
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CL2.5(10.5)Ag0.75(7)PVA10(3.5)  and  CM2.5(7)Ag1(7)PVA10(7)).  Formulations  CM1.25(22)Ag2(20)  and  CM1.25(10.5)Ag2(10.5) 
also  showed a  similar order of  sensitivity as observed  in CL1.25(9)Ag2(12). The  increased viscosity  in 
CM1.25(22)Ag2(20) and CM1.25(10.5)Ag2(10.5) may increase entrapment of Ag+ within the hydrogel, leading to a 










reported  in  Low  et  al.,  2011  [43],  i.e.,  C.  albicans  >  P.  aeruginosa  >  S.  aureus,  for  low‐  and   
medium‐viscosity but not high‐viscosity chitosan hydrogels. Formulation CL1.25(12)TTO‐Ag20‐0.5(3)Na‐
P25(1)PVA10(5)‐CL1.25(9.5)TTO‐Ag20‐1(11.5) (Figure 6A) shows that the antimicrobial activity of the hydrogels 
is dependent on  the viscosity and Ag+ content  in  the system. Higher viscosity with  increased Ag+ 
Figure 5. Antimicrobial activity of Ag+ hydrogels formulated with (A) low-viscosity chitosan;
(B) medium-viscosity chitosan; and (C) high-viscosity chitosan. Error bars represent the standard
deviation and n = 3. In all control experiments (using hydrogels without Ag+), there was no observed
ZOI (data not shown). Statistical analysis using ANOVA indicated no significant difference in the
antimicrobial activity of the formulations against the selected microorganisms (p > 0.05). The codes
shown in the figure key describe the following: CL1.25 = 1.25% w/v low-viscosity chitosan, CL2.5 = 2.5%
w/v low viscosity chitosan, CM1.25 = 1.25% w/v medium iscosity chitosan, CM2.5 = 2 5 w/v
medium-viscosity chitosan, CH1.25 = 1.25% w/v high-viscosity chitosan, CH2.5 = 2.5% w/v high-viscosity
chitosan, Ag0.75 = 0.75% w/v AgNO3 solution, Ag1 = 1.0% w/v AgNO3 solution, Ag2 = 2.0% w/v
AgNO3 solution, PVA = PVA 30–70 kDa and the volume of the components used in each formulation
are shown in the brackets.
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In Figure 5A, formulations with >0.2117% w/v Ag+ (CL1.25(9)Ag2(12)-CL1.25(8)Ag2(13)) all showed
a ZOI against C. albicans, unlike formulations CL2.5(28)Ag2(7)PVA10(7) and CL2.5(10.5)Ag0.75(7)PVA10(3.5).
The observed ZOI was not influenced by the small increase in Ag+ concentration from 0.635% to
0.786% w/v. All formulations showed a ZOI against P. aeruginosa and S. aureus. The increase
in Ag+ from CL1.25(9)Ag2(12) to CL1.25(8)Ag2(13) showed a gradual increase in ZOI, although this
increase was not significant (p > 0.05). This may be due to the higher free Ag+ MLC of P. aeruginosa
(1.59 ˆ 10´3 % w/v) and S. aureus (5.08 ˆ 10´3 % w/v) compared to C. albicans (6.35 ˆ 10´4
% w/v) [43]. Medium-viscosity chitosan hydrogels (Figure 5B) showed relatively similar ZOI
when compared to those in Figure 5A with comparable amounts of Ag+ (CL2.5(28)Ag2(7)PVA10(7)
and CM2.5(10)Ag1(5)PVA10(6); CL2.5(10.5)Ag0.75(7)PVA10(3.5) and CM2.5(7)Ag1(7)PVA10(7)). Formulations
CM1.25(22)Ag2(20) and CM1.25(10.5)Ag2(10.5) also showed a similar order of sensitivity as observed in
CL1.25(9)Ag2(12). The increased viscosity in CM1.25(22)Ag2(20) and CM1.25(10.5)Ag2(10.5) may increase
entrapment of Ag+ within the hydrogel, leading to a slight increase in the ZOI against P. aeruginosa and
S. aureus. However, this is not observed in C. albicans, as the slower release lowered the availability of
Ag+, making it difficult to overcome the reaction with MEA and to express antimicrobial activity.
A similar trend applies when hydrogels formulated with high-viscosity chitosan were used, e.g.,
formulation CH1.25(14)Ag2(10.5) in Figure 5C. The higher viscosity of hydrogels in Figure 5C altered
the order of sensitivity to P. aeruginosa being most sensitive, followed by C. albicans and S. aureus.
Disregarding C. albicans, this trend of sensitivity showed similarities to the results obtained from the
MLC of free Ag+ [43]. In addition to the high viscosity, the interaction between the Ag+ and MEA
makes it more difficult to monitor the actual extent of antimicrobial activity against C. albicans.
According to Figure 6, the order of sensitivity generally follows the MLC response for
free agents reported in Low et al., 2011 [43], i.e., C. albicans > P. aeruginosa > S. aureus,
for low- and medium-viscosity but not high-viscosity chitosan hydrogels. Formulation
CL1.25(12)TTO-Ag20´0.5p3qNa-P25(1)PVA10(5)-CL1.25(9.5)TTO-Ag20´1p11.5q (Figure 6A) shows that the
antimicrobial activity of the hydrogels is dependent on the viscosity and Ag+ content in the
system. Higher viscosity with increased Ag+ forms gels with better stability for entrapment
of agents and reduces burst release of agents via erosion. Nevertheless, such properties may
allow controlled release to be achieved for sustained antimicrobial activity against less sensitive
microorganisms. Small increments in ZOI of the microorganisms were observed as the concentration of
agents increased (formulations CL1.25(12)TTO-Ag20´0.5p3qNa-P25(1)PVA10(5)-CL1.25(9.5)TTO-Ag20´1p11.5q,
except CL1.25(12)TTO-Ag20´0.5p3qNa-P25(1)PVA10(5) against C. albicans). The lower Ag+ content in
CL1.25(12)TTO-Ag20´0.5p3qNa-P25(1)PVA10(5) may reduce crosslinking to enable a faster release of
TTO. Thus, the observed higher ZOI may be due to C. albicans having higher sensitivity to
TTO. Similarly, this was also observed in the ZOI of formulations CM2.5(11)TTO-Ag20´1p6qPVA10(4),
CM2.5(7)TTO-Ag20´1p7qPVA10(7) and CM1.25(10)TTO-Ag20´1p11q (Figure 6B) against C. albicans. The higher
concentration of TTO in formulation CM2.5(7)TTO-Ag20´1p7qPVA10(7) (0.1058% w/v Ag+ and
13.333% v/v TTO) resulted in the higher C. albicans ZOI compared to a relatively similar
counterpart, formulation CM2.5(11)TTO-Ag20´1p6qPVA10(4) (0.1814% w/v Ag+ and 5.7143% v/v
TTO). The ZOI of S. aureus and P. aeruginosa remained fairly consistent between formulations
CM1.25(12)TTO-Ag20´0.5p3qNa-P25(0.75)PVA10(5.25)- CM1.25(10)TTO-Ag20´1p11q.
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Figure 6. Antimicrobial activity of Ag+ + : hydrogels formulated with (A) low-viscosity
chitosan; (B) medium-viscosity chitosan; and (C) high-viscosity chitosan. Error bars represent the
standard deviation and n = 3. In all control experiments (using hydrogels without Ag+ + TTO: PVA),
there was no observed ZOI (data not shown). Statistical analysis using ANOVA indicated a significant
difference in the antimicrobial activity of the formulations against the selected microorganisms
(p < 0.05). The codes shown in the figure key describe the following: CL1.25 = 1.25% w/v low-viscosity
chitosan, CL2.5 = 2.5% w/v low-viscosity chitosan, CM1.25 = 1.25% w/v medium-viscosity chitosan,
CM2.5 = 2.5% w/v medium-viscosity chitosan, CH1.25 = 1.25% w/v high-viscosity chitosan, CH2.5 = 2.5%
w/v high-viscosity chitosan, TTO-Ag20´0.5 = 40% TTO: 0.5% AgNO3, TTO-Ag20´1 = 40% TTO:
1.0% AgNO3, Na-P25 = 25% w/v sodium phosphate, PVA = PVA 30–70 kDa and the volume of
the components used in each formulation are shown in the brackets.
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High-viscosity chitosan hydrogels (Figure 6C) showed slight variation from the MLC data.
The order of sensitivity is P. aeruginosa ě C. albicans > S. aureus. Similar to all the other formulations,
the overall viscosity of the system, the crosslinking capacity of Ag+ and the amount of TTO affect the
antimicrobial activity of the formulations.
Nevertheless, hydrogels containing both TTO and Ag+ managed to maintain their antimicrobial
activity despite having agent concentrations lower than those in TTO or Ag+ hydrogels. For example,
formulation CH2.5(21.5)TTO-Ag20´1p3.5qPVA10(14), containing 0.0570% w/v Ag+ and 1.795% v/v TTO,
maintained antimicrobial activity when compared to similar formulations (e.g., CH2.5(14)Ag2(2)PVA10(5)
containing 0.0605% w/v Ag+, and CH2.5(10)Na-P50(1)TTO35(4)PVA10(6) containing 6.6667% v/v TTO).
At low concentrations of Ag+, formulation CH2.5(14)Ag2(2)PVA10(5) did not show a clear ZOI against
C. albicans, while formulation CH2.5(10)Na-P50(1)TTO35(4)PVA10(6) did not show a clear ZOI against
P. aeruginosa, despite having higher TTO content. The ZOI observed for S. aureus remained fairly
consistent when comparing the hydrogels formulated with varying chitosan viscosity. The maintenance
of activity when using both agents at lower concentrations demonstrates the feasibility of using
combined agents at lower effective concentrations.
Incorporation of TTO and/or Ag+ into chitosan hydrogels demonstrated the possibility of
maintaining antimicrobial activity when using a delivery system. The capacity and performance
of antimicrobial agents varies depending on the type of dressing and wound. For the treatment of
moist wounds, e.g., ulcers, the absorptive properties of hydrogels make them a better option compared
to non-absorptive dressings such as gauzes. Research indicated that there is no single dressing that can
produce the optimum microenvironment for all wounds [44], thus the characteristics of formulations
and delivery systems need to be tailored to suit the wound site.
Factors such as the differences in physicochemical properties of the hydrogels, including chitosan
viscosity, concentration of the crosslinker (Na-P or AgNO3) and the amount of available antimicrobial
agent (Ag+ or TTO), may result in the observed varying order of sensitivity between formulations.
Low-, medium- and high-viscosity chitosans derive their rheological properties from the increasing
chain length of the polymer. Within each of these groups the concentration of chitosan and the degree of
crosslinking also influence viscosity. In addition, increasing the amount of Na-P improves crosslinking
and increases hydrogel stability.
Changes in TTO composition in the hydrogels may occur due to the loss of volatile TTO
components during the gel setting period. The availability of Ag+ varies according to the concentration
required for crosslinking (AgNO3 donates the anionic crosslinking nitrate group) and the release of
Ag+ from the hydrogel.
Encapsulation of broad spectrum antimicrobial agents (TTO and/or Ag+) into hydrogel-based
formulations may be a feasible option to enhance biodistribution and biological activity of the agents.
Despite the effectiveness of combined treatments, the toxicity of individual agents towards human host
cells should also be carefully considered. Although toxicity or irritancy are less likely to occur, various
reports of toxicity associated with the misuse/overuse of TTO [12,45], Ag+ and silver-containing
products have been discussed [10,26,28]. Thus, it is important to find an effective lower combination
ratio of TTO and Ag+ concentrations to avoid toxicity issues whilst maintaining antimicrobial
properties. In this investigation, PVA was used to emulsify TTO to form an oil-in-water emulsion.
This will allow more efficient encapsulation into the hydrogels, reducing loss and degradation of
volatile components which may affect the oil’s therapeutic activity [37,44]. Emulsifying essential
oils can also improve hydrophobic and hydrophilic component distribution due to reduced droplet
size [44]. The release kinetics of agents incorporated into chitosan gels may be influenced by factors
such as the morphology, size, density, extent of crosslinking, gel formulation ability and swelling of
the chitosan-based hydrogel [46].
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4. Conclusions
The versatility of these agent(s) against a wide range of different microorganisms due to their
multiple target sites might be used to improve the current treatment strategies for various chronic
wound infections. Combining agents with different intra- and extracellular target sites has two
advantages. One is to limit the development of resistance towards these antimicrobial compounds
by extending the range of target sites. The activity of microbial agents with a single site of action can
much more readily be overcome, thus making it easier for resistance to develop. Another advantage is
to reduce the likelihood of toxic effects.
This study showed the feasibility of developing hydrogels as a controlled release system for the
delivery of TTO and Ag+ in combination. As a whole, the results from this investigation have provided
the basis to develop hydrogel formulations for the delivery of an essential oil (TTO) and metal ion (Ag+)
as antimicrobial agents for the treatment of acute wounds. The relationship between the variables
in the hydrogel formulations and antimicrobial activity requires further work. Consequently, the
characteristics of the hydrogel formulations, including the encapsulated agent concentration, can be
modified to enhance their potential as a smart delivery system.
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